Johnson & Johnson’s Norwegian pharmaceutical business will close, while medicine supply and ongoing trials will continue.
Johnson & Johnson (J&J) has decided to wind down its pharmaceutical operations in Norway after what it describes as a thorough review of the framework for innovative medicines. Its MedTech business is not affected.
J&J has not specified the factors behind the decision. It also has not responded to questions about consequences for employees or where market access, medical information and engagement with Norwegian authorities and health services will be managed.
LMI reflects on this decision
The Norwegian Pharmaceutical Industry Association (LMI) says the decision illustrates a risk it has long highlighted: slow uptake of new treatments and low prices may make Norway less relevant for commercial presence, investment and clinical studies. LMI says they do not know about the specific reasons behind J&J’s decision though.
LMI cites EFPIA Patients W.A.I.T. data: 59 of 168 medicines approved by EMA in 2021–2024, or 35%, had publicly funded access in Norway on 5 January 2026, versus a European average of 45%.
J&J says it will ensure treatment continuity and complete ongoing clinical studies.
Read more at https://www.healthtalk.no/nyheter-og-politikk/lmi-etter-jjs-norge-exit-dette-er-risikoen-vi-har-advart-mot/216567
